IMRX — Immuneering Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1790340 ·
Last close
$3.46
Market Cap
$224.08M
52W High
$8.48
52W Low
$3.32
ADV30
812,585
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -25,787,560 | -24,192,583 | 182,561,047 | 58,226,805 | 13,880,350 |
| Jun 2026 | 0 | — | -18,999,964 | -17,270,427 | 202,055,327 | 41,324,682 | 11,320,301 |
| Mar 2026 | 0 | — | -15,334,539 | -13,460,895 | 214,809,790 | 47,321,566 | 8,291,619 |
| Dec 2025 | 0 | — | -13,751,943 | -11,580,010 | 231,985,010 | 128,645,025 | 13,501,042 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,752,670
Investing CF
$-141,318,060
Financing CF
$213,039,914
CapEx
$-238,462
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,051,406
Inventory
—
Receivables
—
ST Investments
$108,575,637
EBIT TTM
$-63,466,746
Pretax Income TTM
$-57,274,086
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,375,728 | -56,024,898 | 231,985,010 | 13,501,042 | 218,483,968 | -45,344,595 |
| Dec 2024 | 0 | -64,071,655 | -61,036,608 | 52,714,413 | 11,328,187 | 41,386,226 | -54,999,571 |
| Dec 2023 | 0 | -58,413,285 | -53,471,622 | 102,584,538 | 12,008,355 | 90,576,183 | -48,968,634 |
| Dec 2022 | 316,952 | -51,745,339 | -50,513,568 | 122,367,283 | 12,517,028 | 109,850,255 | -44,101,265 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$4,720,061
NetIncome TTM
$-57,276,207
OpCashFlow TTM
—
Assets (Latest)
$202,055,327
Forward EPS
$-1.26
Max Pain — expiry 2027-01-15
max pain strike: $5.00 · spot: $3.50 · call oi: 899 · put oi: 605
Expected Move to 2027-01-15:
±$1.18
(33.57%) —
implied range
$2.33 –
$4.67
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | $221.95M | $11.31 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $229.72M | $7.97 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $230.39M | $3.81 | — |
| PRLD | Prelude Therapeutics Inc | $216.05M | $3.32 | — |
| FTH | Faeth Therapeutics, Inc. | $233.63M | $9.04 | — |
News headlines (Yahoo Finance, 1h cache)
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
2026-11-18 12:30 · Yahoo
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
2026-11-18 12:30 · Yahoo
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
2026-11-13 14:36 · Yahoo
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
2026-11-12 12:30 · Yahoo
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
2026-11-12 12:30 · Yahoo
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
2026-11-09 12:30 · Yahoo
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
2026-11-06 14:00 · Yahoo
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-04 21:05 · Yahoo
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
2026-11-04 12:30 · Yahoo
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-10-29 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.